Glenmark Pharma’s innovation arm, IGI, received FDA fast track designation for its myeloma therapy ISB 2001, targeting heavily pre-treated RRMM patients. The tri-specific antibody showed high response rates and a favorable safety profile in early trials. Complete results will be presented at ASCO 2025. The stock rose 2.2% on Monday, with analysts maintaining a ‘Buy’ rating.
Positive Breakout: These 8 stocks cross above their 200 DMAs
As of July 29, 2026, 18 Nifty 500 stocks closed above their 200-day moving average (DMA). Among them, we highlighted the top eight that gained